| Předmět: |
|
| Zdroj: |
Biomedical Market Newsletter; 11/14/2011, Vol. 21, p728-730, 3p |
| Abstrakt: |
The article reports on the operational progress of BrainStorm Cell Therapeutics Inc. in 2011. The Israeli subsidiary of the company has received grants from Israel's Office of the Chief Scientist. The company has entered a Memorandum of Understating with Massachusetts General Hospital and the University of Massachusetts Medical School to begin amyotrophic lateral sclerosis (ALS) human clinical trial. It has also started the Phase I/II clinical trial with its NurOwn (tm) treatment for ALS. |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
